ProStrakan rebrands as Kyowa Kirin

ProStrakan, the Scotland-based specialty pharmaceutical company, announces today (18th April, 2016) that it is rebranding as Kyowa Kirin from today’s date.

ProStrakan was acquired by Tokyo-based Kyowa Hakko Kirin Co. Ltd. (KHK) in 2011 and the Japanese company has decided that, in order to present a consistent image across the world, all of its western pharmaceutical subsidiaries are to adopt the Kyowa Kirin name. ProStrakan’s Galashiels headquarted business will trade as Kyowa Kirin International PLC with its various country affiliates adopting the Kyowa Kirin name into their local company titles.

Aside from the name change itself, the move will have no impact on the business, which operates across Europe and the United States of America.

Dr Tom Stratford, Chief Executive of Kyowa Kirin International, said:

“KHK’s ambition is to grow a global pharmaceuticals business. The business is entering an exciting launch phase for its pipeline of near-to-market products and this is a logical time for the company to unify all of its operating companies under the Kyowa Kirin name across Asia, Europe and the US.

“We are proud of our heritage as ProStrakan and of the part we play in the KHK group. We plan to adopt the Kyowa Kirin identity over the course of 2016 and I am confident
that we will continue to play a significant role in the Scottish life sciences sector and in our markets across Europe and the US."

Ends

18th April, 2016

Further enquiries:
Callum Spreng              Tel: +44 (0)141 548 5191
Spreng Thomson            Mob: +44 (0)7803 970103
(for Kyowa Kirin International) Email: callum@sprengthomson.com

About Kyowa Kirin International
Kyowa Kirin International is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets. Headquartered in Galashiels, Scotland, it is a subsidiary of Kyowa Hakko Kirin Co., Ltd., the Japan-based global specialty pharmaceutical company. Sales and marketing of its portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain, Italy and other EU countries. You can learn more about the business at: www.kyowa-kirin.com.

About Kyowa Hakko Kirin
Kyowa Hakko Kirin is a research-based life sciences company with special strengths in biotechnologies. In the core therapeutic areas of oncology, nephrology and immunology/allergy, Kyowa Hakko Kirin leverages leading-edge biotechnologies centered on antibody technologies, to continually discover innovative new drugs and to develop and market those drugs world-wide. In this way, the company is working to realise its vision of becoming a Japan-based global specialty pharmaceutical company that contributes to the health and comfort of people around the world.